Paclitaxel (Phyxol) and Cisplatin as First-line Chemotherapy for Metastatic Breast Cancer
Status:
Unknown status
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
The primary endpoint of this phase II trial is the objective response rate of the stage I
(low-dose) regimen. The secondary endpoints include treatment-related toxicity, the change in
quality of life, progression free survival and overall survival.